Panobinostat (Farydak®)

Assessment Status Rapid Review Complete
Drug Panobinostat
Brand Farydak®
Indication In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.
Assessment Process
Rapid review commissioned 26/01/2016
Rapid review completed 09/02/2016
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation